Semax research overview

Molecular overview

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design is based on an ACTH fragment with a proline-rich tail, while lacking the full hormone’s corticotropic activity.

Research pathways

Rodent studies have examined brain-derived neurotrophic factor expression, monoamine systems and transcriptional changes after experimental cerebral ischemia. Genome-wide studies report changes across immune-response, interferon and vascular pathways.

Because these measurements come from specific animal models, they should be treated as hypotheses about pathway modulation—not as evidence of a human cognitive or neurological outcome.

Published-research summary

The indexed evidence is dominated by rodent mechanistic studies. Clinical reports originate mainly from Russian practice and do not provide the kind of large, independently replicated, U.S.-registered trial record needed for strong conclusions.

Analytical testing methodology

Expected molecular mass and chromatographic behavior are distinct quality attributes: mass spectrometry supports identity, while HPLC assesses peptide-related peaks. No Novanta PDF is currently posted for Semax, so this page does not imply a lot result that is not available.

Storage and stability

No compound-specific shelf life is stated without formulation-specific stability data. Protect sealed lyophilized research material from light and moisture, and validate any prepared solution over the actual temperature and time range used in the experiment.